Doctors to be on guard for meningitis in kids
By Will Dunham
WASHINGTON (Reuters) - U.S. health officials asked doctors on Thursday to be alert for possible cases of meningitis and other illnesses in children caused by Hib bacteria amid an ongoing vaccine shortage.
Officials are most concerned about bacterial meningitis and sepsis, a bloodstream infection, caused by Hib (Haemophilus influenzae type b) in children under age 5 because of the high risk of death or serious complications, Centers for Disease Control and Prevention epidemiologist Mike Jackson said.
Meningitis is the inflammation of the tissue surrounding the brain and spinal cord, and can be caused by viral or bacterial infections. Before the vaccines, Hib was the most common cause of bacterial meningitis.
Merck & Co Inc last year recalled its Hib vaccines because production equipment may not have been properly sterilized. Merck initially said the PedvaxHIB and COMVAX vaccines would return to the U.S. market late this year, but in October said they would not do so until mid-2009.
Hib vaccine made by Sanofi Pasteur, the vaccines division of Sanofi-Aventis, remains available. But because of the absence of the Merck vaccines, the CDC has asked doctors to postpone the routine Hib vaccine booster doses typically given at age 12- to 15 months until the vaccine supply improves.
Because of the Sanofi supply, Jackson said there is enough vaccine to give children the primary vaccine series — doses at 2, 4 and 6 months of age — but not the booster doses.
With the vaccine shortage, children who otherwise might be fully protected against Hib could be vulnerable. Jackson said the CDC wants doctors to notify local health departments if they come across cases of Hib disease in children and get a clinical specimen for confirmation of the illness.
(Editing by Vicki Allen)
--------------------------------------------------------------------------------------------Related Posts:
LONDON (Reuters) - Giving just one fifth the dose of a commonly used meningitis vaccine may be as effective as using the full dose, researchers said on Tuesday. The finding should allow medics to stretch scarce vaccine resources, especially during epidemics in Africa. A clinical study conducted in Uganda by Epicentre — the research arm of medical
Full Post: Partial vaccine dose may work as well as full shot
--------------------------------------------------------------------------------------------
By Julie Steenhuysen CHICAGO (Reuters) - A routine childhood vaccine used to prevent several common types of infections has helped cut the rate of a deadly form of meningitis by 30 percent in children and adults, U.S. researchers said on Wednesday, suggesting even the unvaccinated are benefiting from the shot. They said the vaccine Prevnar made by
Full Post: Vaccine cuts meningitis rates, even in adults
--------------------------------------------------------------------------------------------
By Tan Ee Lyn HONG KONG (Reuters) - French drugmaker Sanofi-Aventis hopes to sell 25 million doses of seasonal flu vaccine annually into China’s largely untapped domestic market once its plant in the southern city of Shenzhen goes onstream in 2012. Wayne Pisano, head of the company’s vaccines arm Sanofi-Pasteur, said on Monday only two percent of
Full Post: Sanofi-Aventis to market seasonal flu vaccine in China
--------------------------------------------------------------------------------------------
By Gene Emery BOSTON (Reuters) - A newer vaccine that targets the most common form of the polio virus works up to four times better than the conventional vaccine that tries to protect against all three types of the crippling disease, researchers said on Wednesday. The monovalent vaccine may help speed the fight to eradicate polio, U.S.
Full Post: Newer vaccine seen as better for polio hot spots
--------------------------------------------------------------------------------------------
NEW YORK (Reuters Health) - A combination vaccine against diphtheria, tetanus, pertussis, polio and flu, which is routinely used in Canadian children, has been shown to be effective and well tolerated in a U.S. study. The randomized trial was conducted to support U.S. licensure of the vaccine known as DTaP5-IPV-Hib, which incorporates diphtheria-tetanus-5-component acellular pertussis (DTaP5),
Full Post: Combination vaccine safe and effective for infants